A phase 1b study of ruxolitinib (Rux) + gemcitabine (G) ± nab-paclitaxel (N) in patients (pts) with advanced solid tumors
Bauer, Todd Michael, Patel, Manish R., Wood, Tina Evans, George, Thomas J., Dawkins, Fitzroy W., Brill, Kimberli J., Du, Yining, Hurwitz, Herbert
Published in Journal of clinical oncology (01.02.2017)
Published in Journal of clinical oncology (01.02.2017)
Get full text
Journal Article
CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab -paclitaxel ( nab -P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC)
Chiorean, E. Gabriela, Von Hoff, Daniel D., Ervin, Thomas J., Arena, Francis P., Infante, Jeffrey R., Bathini, Venu Gopal, Wood, Tina Evans, Mainwaring, Paul N., Muldoon, Robert T., Clingan, Philip R., Kunzmann, Volker, Ramanathan, Ramesh K., Tabernero, Josep, Goldstein, David, Ko, Amy, Lu, Brian
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article